Autonomix Medical, Inc. AMIX

Company Overview

Autonomix Medical, Inc. is a medical device company focused on developing technologies for the diagnosis and treatment of diseases involving the peripheral nervous system. The company operates within the medical technology and interventional therapeutics industries, with a primary emphasis on catheter-based nerve sensing and radiofrequency ablation solutions intended to support minimally invasive procedures. Its core platform is designed to detect and differentiate neural signals with greater sensitivity than conventional technologies, with initial clinical applications targeting pain management associated with pancreatic cancer and other conditions linked to overactive sympathetic nervous system activity.

The company’s principal revenue and value driver is the development and commercialization potential of its proprietary catheter-based sensing and ablation platform rather than established product sales. Autonomix has positioned itself around the concept of precision nerve targeting, aiming to improve procedural accuracy in interventional medicine. The company evolved from early-stage neurotechnology development efforts into a publicly traded medical technology business focused on advancing clinical validation, regulatory milestones, and strategic partnerships. Public disclosures indicate that its business model remains heavily oriented toward research, development, clinical trials, and future commercialization opportunities rather than mature recurring operating revenue.

Business Operations

Autonomix Medical conducts its operations primarily through a single integrated medical device development platform centered on its proprietary nerve detection and radiofrequency ablation technology. The company’s activities include device engineering, software and signal-processing development, preclinical validation, regulatory engagement, and clinical study execution. Its technology platform combines microchip-based sensing capabilities with catheter-based delivery systems intended for minimally invasive intervention. Public filings indicate that the company has concentrated its initial clinical strategy on pancreatic cancer pain management, where targeted nerve ablation may reduce severe pain symptoms associated with advanced disease.

Operations are primarily based in the United States, although the company has discussed opportunities for broader international clinical and commercial expansion depending on regulatory progress and partnership development. Autonomix relies on intellectual property protection, proprietary signal detection methodologies, and specialized catheter technologies as core strategic assets. Available public disclosures do not indicate a large portfolio of operating subsidiaries or diversified business units, and the company appears to function primarily as a focused development-stage enterprise. Data regarding large-scale commercial joint ventures or material international operating partnerships remains inconclusive based on available public sources.

Strategic Position & Investments

Autonomix Medical’s strategic direction has centered on advancing its proprietary nerve sensing and ablation platform through clinical development and regulatory progression. The company has emphasized building clinical evidence around the ability of its technology to selectively identify neural signals and improve targeting precision during interventional procedures. Its growth initiatives have included clinical studies, intellectual property expansion, and efforts to establish physician adoption pathways in interventional oncology and pain management settings. Public company disclosures and investor materials indicate that management views the technology as potentially applicable across multiple disease states involving dysfunctional nerve signaling.

The company’s investments have primarily focused on research and development, clinical trial execution, engineering refinement, and regulatory preparation rather than large-scale acquisitions. Autonomix has also highlighted opportunities in emerging fields tied to bioelectronic medicine, precision nerve modulation, and minimally invasive therapeutic intervention. While the company has referenced broader future applications for its platform, commercial adoption and scalability remain dependent on clinical outcomes, regulatory approvals, reimbursement pathways, and additional capital access. Publicly available information does not indicate a diversified portfolio of major subsidiary businesses or extensive acquisition activity.

Geographic Footprint

Autonomix Medical is headquartered in the United States, with corporate operations and development activities primarily concentrated domestically. Its public filings indicate that the company’s principal operational focus has been on U.S.-based clinical development, regulatory engagement, and technology advancement. The company’s initial market strategy appears centered on the North American healthcare and interventional medicine ecosystem, particularly among physicians and institutions involved in oncology-related pain management and minimally invasive procedures.

Although the company has discussed broader commercialization opportunities, its international operational footprint remains limited relative to larger multinational medical device companies. Available public information suggests that international expansion opportunities may depend on future regulatory clearances, strategic partnerships, and clinical adoption outside the United States. Data regarding significant direct operating infrastructure across Europe, Asia-Pacific, or other regions is inconclusive based on available public sources.

Leadership & Governance

Autonomix Medical is governed as a publicly traded medical technology company with leadership focused on advancing clinical-stage innovation, intellectual property development, and regulatory execution. The company’s governance structure reflects its status as a development-stage enterprise, with executive leadership emphasizing capital formation, technology validation, and strategic commercialization planning. Public communications and filings indicate that management has prioritized clinical evidence generation and physician engagement as central elements of the company’s strategic vision.

Key executives and leadership figures publicly associated with the company include:

• Brad Hauser – Chief Executive Officer
• Lori Bisson – Chief Financial Officer
• Dr. Robert Duggan – Director
• Dr. Mark B. Pomeranz – Chief Medical Officer

Leadership and governance information has been verified through publicly available company filings, investor materials, and market disclosures. Some executive roles and board compositions may change over time following corporate updates or SEC reporting periods.